Pipeline
Advancing drug candidates with the goal of delivering transformative medicines for patients
Our ReSOLVE™ platform enables a highly differentiated pipeline of small molecule therapeutics for highly validated innate immunity targets. Our lead programs target the inflammasome and nucleic acid sensing pathways. We have multiple programs in discovery and are pursuing a broad pipeline of additional targets.
| Program | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|
| VENT-03 (Oral cGAS inhibitor) | |||||
| Lupus | |||||
| Treatment-Refractory Rheumatoid Arthritis | |||||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | |||||
| Parkinson’s Disease | |||||
| Osteoarthritis in Obese Patients | |||||
| VENT-01 (Oral systemic NLRP3 inhibitor) | |||||
| Broad range of systemic diseases |  | ||||
| Multiple programs in discovery, powered by ReSOLVE® | ||||
| VENT-03 (Oral cGAS inhibitor) | ||
| Lupus | ||
| Phase 1 | ||
| Treatment-Refractory Rheumatoid Arthritis | ||
| Phase 1 | ||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | ||
| Parkinson’s Disease | ||
| Phase 2 | ||
| Osteoarthritis in Obese Patients | ||
| Phase 1 | ||
| VENT-01 (Oral systemic NLRP3 inhibitor) | ||
| Broad range of systemic diseases | ||
| Phase 1 | ||
Multiple programs in discovery, powered by ReSOLVE®
